NCT02629575已完成不适用
Coroflex ISAR 2000 Postmarket Surveillance Non-Interventional Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 2,877
- 试验地点
- 3
- 主要终点
- clinically driven Target Lesion Revascularization
研究概览
简要总结
Postmarket surveillance in terms of the safety and efficacy of Sirolimus-eluting Coroflex ISAR Stent for the treatment of "real world" patients with de-novo and restenotic lesions after stand-alone angioplasty in coronary arteries
详细描述
The aim of the study is to assess the safety and efficacy of elective deployment of the Sirolimus-eluting Coroflex ISAR Stent for the treatment of "real world" de-novo and restenotic lesions after stand-alone angioplasty in coronary arteries of 2.0 mm up to 4.0 mm in diameter and up to 30 mm in length for procedural success and preservation of vessel patency.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients suitable for percutaneous coronary intervention with proof of ischemia
- •at least 18 years of age
排除标准
- •Intolerance to sirolimus and/or probucol
- •Allergy to components of the coating
- •Pregnancy and lactation
- •Complete occlusion of the treatment vessel
- •Severely calcified stenosis
- •Cardiogenic shock
- •Risk of an intraluminal thrombus
- •Haemorrhagic diathesis or another disorder such as gastro-intestinal ulceration or cerebral circulatory disorders which restrict the use of platelet aggregation inhibitor therapy and anti-coagulation therapy
- •Surgery shortly after myocardial infarction with indications of thrombus or poor coronary flow behavior
- •Severe allergy to contrast media
- •Lesions which are untreatable with PTCA or other interventional techniques
- •Patients with an ejection fraction of < 30 %
- •Vascular reference diameter < 2.00 mm
- •Treatment of the left stem (first section of the left coronary artery)
- •Indication for a bypass surgery
- •Contraindication for whichever accompanying medication is necessary
结局指标
主要结局
clinically driven Target Lesion Revascularization
时间窗: 9 months
re-intervention of the target lesion
次要结局
- Cardiac death rate(9 months)
- Myocardial infarction rate(9 months)
- Stent thrombosis rates(0-9 months)
- Target lesion revascularization rate(9 months)
- Major Adverse Cardiac Events(9 months)
- Procedural success(immediately after stent implantation (within the first 30 minutes))
研究者
研究点 (3)
Loading locations...
相似试验
已完成
不适用
Coroflex ISAR 2000 Extended Registry (ISAR2000 Extended)Coronary Artery Disease (CAD)NCT02905214B. Braun Melsungen AG4,369
招募中
不适用
Coroflex® ISAR NEO PMCF StudyCoronary Artery Disease (CAD)Ischemic Heart DiseaseNCT05698732Fundación EPIC3,000
招募中
不适用
IRIS-Coroflex NEO CohortCoronary Artery StenosisCoronary Artery DiseaseNCT06177743Seung-Jung Park1,000
Unknown
4 期
ISAR-DAPT (A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial)Stable Angina, Unstable Angina, Silent Coronary Ischemia, Coronary Artery DiseaseNCT02609698Ajou University School of Medicine906
已完成
4 期
Study Evaluating Sirolimus in Kidney Transplant Recipients in IndiaKidney FailureGraft vs Host DiseaseNCT00195481Wyeth is now a wholly owned subsidiary of Pfizer100